Bravo brings more than 25 years’ experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations.
Since 2011, as CEO of TiGenix, a dual-listed (Euronext Brussels and NASDAQ) biopharmaceutical company developing novel stem cell therapies, he developed the company through several financing rounds, led its IPO on NASDAQ, and secured European marketing approval of its lead asset, reports Nordic Nanovector. In January 2018, Takeda Pharmaceutical Co. Ltd announced it was acquiring TiGenix for €520 million.
Prior to joining TiGenix’ predecessor, Cellerix, in 2005, Bravo held several senior management positions at Sanofi-Aventis and SmithKline Beecham. He is currently Chairman of Vivet Therapeutics. He holds a degree in Business Administration and an MBA (INSEAD).
An exciting future
“I am looking forward to this exciting new role as the CEO of Nordic Nanovector. It is clear that the company has an exciting future based on the significant potential of Betalutin in follicular lymphoma and NHL more broadly. I am joining an excellent board and management team and am confident that with my complementary experience and networks, we can succeed with Betalutin to provide physicians with another treatment option to improve the lives of patients who are in dire need of effective therapies to control their disease and build significant value in the company,” says Eduardo Bravo.
On joining Nordic Nanovector, Mr Bravo will be granted 250,000 PSUs (performance share units) and the company’s Board of Directors has undertaken to grant him a further 50,000 PSUs as part of the company’s annual grant of PSUs in the first quarter of 2019. For further information about the PSUs and the related warrants, see pages 66-68 in the company’s annual report for 2017. In addition, on joining Nordic Nanovector, Mr Bravo will receive a sign-on bonus of EUR 50,000 and has undertaken to invest, at minimum, the net amount after tax in Nordic Nanovector shares and will do so following this announcement.
Mr Bravo took up the CEO position in Nordic Nanovector on 2 July and will be based in London, UK.